ClinicalTrials.gg
CompletedNCT00630630Updated Nov 26, 2013

Study on Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Female Subjects With C1 Catamenial Epilepsy

A Phase 4 interventional study of Levetiracetam and Placebo in Epilepsy, sponsored by UCB Pharma. Completed. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2013-11-26.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 60 studies testing levetiracetam in Epilepsy — 4 open to participants now, 4 under way, 2 of them phase 3. Levetiracetam · Epilepsy.

Enrollment
59th of 60
3 · median 94
Started
2002
with 2 others
Phase 4
13 of 60
1 open now
Registered
29th of 60
by date
Lead sponsor
23 of 60
UCB Pharma

Among the 60 studies testing levetiracetam in Epilepsy, this one is the 59th largest by enrollment, is one of 3 that started in 2002, is one of 13 in phase 4, and was the 29th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

4 of the 60 studies testing levetiracetam in Epilepsy are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About levetiracetam

Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 282 Epilepsy studies recruiting now, 112 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing levetiracetam in Epilepsy, or all of them as a file.
02

Study summary

The relationship between hormone cycling/fluctuations and the occurrence of seizures in women has received considerable discussion in the medical literature. This study investigated the efficacy and tolerability of LEV treatment for subjects with catamenial exacerbation of partial onset seizures.

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Levetiracetam
  • Keppra
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-pregnant and non-nursing females between the ages of 18 - 45 years of age;
  • out-patients with epilepsy experiencing uncontrolled simple and/or complex partial seizures with or without secondary generalization for a minimum of 2 years;
  • classifiable epilepsy according to the International Classification of Epileptic Seizures;
  • minimum of 2 seizures per 4 weeks during the Baseline Period, without exceeding 100 seizures per 4 weeks. The majority of seizures (>50%) must be partial onset, with or without secondary generalization;
  • exhibited, during the Baseline Period, a catamenial epilepsy type C1 pattern defined as at least a 70% increase of weekly seizure frequency during the menstrual phase compared to the luteal and follicular phases combined;
  • concurrent C2 catamenial epilepsy, defined as a 70% increase in daily seizure average during the ovulatory phase in comparison to the follicular and luteal phases combined, was permitted;
  • taking a minimum of one and a maximum of two antiepileptic drugs at a stable dose for a period of 4 weeks prior to the selection visit and during the duration of the trial;
  • vagal nerve stimulator (VNS) was permitted.

Exclusion criteria

Exclusion Criteria:

  • using felbatol and presented abnormalities with WBCs, RBCs, , and/or hepatic function during felbatol treatment, and taking felbatol less than one year from the date of the Selection Visit;
  • partial onset seizures uncountable due to clustering during the last 3 months;
  • hormonal that block menses within 6 months of the selection visit with no permitted;
  • menstrual cycle length less than 21 days and greater than 35 days during the baseline evaluation;
  • alternative medications documented or purported to impact reproductive hormone levels, within the prior 2 months with no washout period permitted;
  • significantly irregular menstrual cycles or a history of frequent amenorrhea defined as two episodes within the preceding 6 months;
  • not taking hormonal contraceptives with more than one anovulatory cycle during the Baseline Period;
  • clinically significant medical condition requiring treatment, except for the study indication, which would prevent clear interpretation of the study results;
  • using the following classes of medications influencing the central nervous system: antipsychotics (typical and atypical), psychostimulants (except those containing methylphenidate, dextroamphetamine, or amphetamine used in the treatment of Attention Deficit Disorder), and hypnotics;
  • chronically dosing with benzodiazepines;
  • hospitalized for depression within 3 months prior to the selection visit.
  • history of attempting suicide within the last 3 years, or suicidal ideation within the last 3 months;
  • recent history (within the past two years) or presence of significant alcohol abuse or drug abuse;
  • clinical history of significantly impaired renal function with a estimate of below 80 ml/min;
  • history of clinically significant cardiac conditions;
  • /SGPT, AST/SGOT, alkaline phosphatase, or ?-GT value of more than 3 times the upper limit of the central laboratory reference value;
  • presence of a terminal illness;
  • presence of any clinically significant allergic condition to levetiracetam or pyrrolidone derivatives;
  • of less than 1800 per ?L.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
3 participants (actual)

Study arms

  • Experimental
    1

    Drug: Levetiracetam

  • Placebo comparator
    2

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percent change in catamenial seizure frequency.

Secondary outcomes

  1. Responder rate

  2. Number of days free from seizures per week

  3. Ratio of catamenial seizure frequency to non-catamenial seizure frequency

  4. Catamenial seizure frequency during each cycle

  5. Seizure frequency of catamenial and non-catamenial combined

  6. Non-catamenial seizure frequency

  7. Catamenial seizure frequency separately for ovulatory and anovulatory cycles

  8. Safety

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2002, a primary completion of Nov 2003 and a completion of Nov 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2008
First posted
Mar 7, 2008
Start
Nov 2002
Primary completionActual
Nov 2003
CompletionActual
Nov 2003
Last update
Nov 26, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00630630
Lead sponsor
UCB Pharma
First posted
Mar 7, 2008
Start date
Nov 2002
Primary completion
Nov 2003
Completion
Nov 2003
Last update
Nov 26, 2013

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion